I agree CGT, I can understand shareholder frustration with the SP but getting the BARDA grant was impressive as is having Relenza selling (though the royalty rate is pitiful for Relenza and LANI) and pipeline drugs such as HRV showing promise.
Less impressive was the handling of the GSK case esp considering they could have got the rights back to Relenza and sold it directly to govt bodies like what they intend to do with LANI but hindsight is a wonderful thing.
I consider Biota to be in the same category as Cochlear/CSL obv w/o the similar performance in SP. To be fair, it is probably more accurate to compare it to Pharmaxis (which is another bio I like).
I just hope they can monetise HRV better than what they did with Relenza.
I don't mind Cook, I feel he knows his stuff, however maybe he doesn't have enough skin in Biota (I'm not sure what his individual holding is).
I have other biotechs where the CEO is the largest holder (and I suppose a good example is MSB) so you know they have a vested interest in the SP performing (though even they are down in this market).
Hopefully Piper Jaffray are helping them out with HRV to get a great deal ala MSB :)
Add to My Watchlist
What is My Watchlist?